Gazyva

(Obinutuzumab)

ApprovedMonoclonal antibody

Obinutuzumab is used to treat certain types of blood cancers, particularly chronic lymphocytic leukemia and follicular lymphoma, by helping the immune system attack cancer cells.[2] Gazyva is currently approved and in use across 57 indications[4].[1]

Gazyva is one of 643 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Approved.

Indications

273

Total Trials

Active Trials

642

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Mantle Cell LymphomaRecruiting

LymphomaRecruiting

Membranous NephropathyRecruiting

Follicular Lymphoma (FL)Active, not recruiting

LenalidomideWithdrawn

Chronic Lymphocytic LeukemiaCompleted

Membranous GlomerulonephritisActive, not recruiting

Idiopathic Membranous GlomerulonephritisActive, not recruiting

Mature B-Cell MalignanciesActive, not recruiting

CCND1 PositiveActive, not recruiting

Mantle Cell LymphomaPhase 2

Recruiting

LymphomaPhase 3

Recruiting

Membranous NephropathyPhase 3

Recruiting

Follicular Lymphoma (FL)Phase 3

Active, not recruiting

LenalidomidePhase 2

Withdrawn

Chronic Lymphocytic LeukemiaPhase 3

Completed

Membranous GlomerulonephritisPreclinical

Active, not recruiting

Idiopathic Membranous GlomerulonephritisPreclinical

Active, not recruiting

Mature B-Cell MalignanciesPhase 1

Active, not recruiting

CCND1 PositivePhase 2

Active, not recruiting

Showing 10 of 57 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Gazyva

Roche

Approved

36 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

CLL

NCT05950997

Q4 2026

Phase 2Recruiting

Mantle Cell Lymphoma

NCT06054776

Phase 2Recruiting

Chronic Lymphocytic Leukemia

NCT05336812

Phase 1/2Active, not recruiting

Follicular Lymphoma

NCT03980171

Phase 2Recruiting

Immune Thrombocytopenia

NCT06094881

Phase 1Active, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

NCT06547944

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia44 trials

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Unknown status·DDeok-Hwan Yang·Phase 2·NCT04059081·31 enrolled

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Terminated· Roche logo

Roche·Phase 1·NCT02336048·38 enrolled

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Terminated· Gilead logo

Gilead·Phase 3·NCT01980875·57 enrolled

Show 41 more trials

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02225275·9 enrolled

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Completed·PPharmacyclics LLC.·Phase 3·NCT02264574·229 enrolled

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Recruiting·OOhio State University Comprehensive Cancer Center·Phase 2·NCT05336812·52 enrolled

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche·Phase 2·NCT02320487·102 enrolled

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 1·NCT01685892·82 enrolled

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Completed· Gilead logo

Gilead·Phase 2·NCT02983617·36 enrolled

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Recruiting·—·Phase 2·NCT07218510·33 enrolled

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed· AbbVie logo

AbbVie·Phase 3·NCT03406156·120 enrolled

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Completed· Roche logo

Roche·Phase 2·NCT01414205·80 enrolled

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 2·NCT01868893·20 enrolled

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Recruiting·OOHSU Knight Cancer Institute·Phase 1·NCT05943496·27 enrolled

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

Completed· Roche logo

Roche··NCT02915224·50 enrolled

Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Completed· Roche logo

Roche··NCT03059251·2 enrolled

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Terminated·TTG Therapeutics, Inc.·Phase 3·NCT02612311·603 enrolled

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT06428019·170 enrolled

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 2·NCT02071225·72 enrolled

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting·IInhye Ahn·Phase 2·NCT06333262·60 enrolled

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Completed· Roche logo

Roche·Phase 1·NCT01300247·41 enrolled

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed· Gilead logo

Gilead·Phase 2·NCT02968563·35 enrolled

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Withdrawn·MMichael Choi·Phase 1·NCT02611908

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

Not yet recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07003464·30 enrolled

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche··NCT03374137·55 enrolled

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Recruiting·PPaolo Caimi, MD·Phase 1·NCT06916767·18 enrolled

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Active, not recruiting·—·Phase 1·NCT02537613·54 enrolled

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT04895436·75 enrolled

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Completed· Roche logo

Roche·Phase 3·NCT02053610·787 enrolled

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05536349·60 enrolled

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Completed· AbbVie logo

AbbVie·Phase 2·NCT05105841·20 enrolled

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04505254·60 enrolled

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Completed· Roche logo

Roche·Phase 3·NCT01010061·787 enrolled

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Completed·—·Phase 1/2·NCT03010358·24 enrolled

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 3·NCT02242942·445 enrolled

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting·KKerry Rogers·Phase 1/2·NCT02427451·87 enrolled

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Completed· Roche logo

Roche·Phase 3·NCT04285567·166 enrolled

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Completed· Roche logo

Roche·Phase 3·NCT01998880·787 enrolled

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT05650723·50 enrolled

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Completed·GGerman CLL Study Group·Phase 3·NCT02950051·926 enrolled

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 3·NCT01905943·979 enrolled

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Completed·GGrupo Cooperativo de Hemopatías Malignas·Phase 2·NCT03755947·3 enrolled

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche·Phase 1·NCT01671904·84 enrolled

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04269902·247 enrolled

Lymphoma33 trials

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03930953·438 enrolled

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT03276468·136 enrolled

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04464798·62 enrolled

Show 30 more trials

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Completed· Roche logo

Roche·Phase 1/2·NCT01691898·231 enrolled

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Completed· Roche logo

Roche·Phase 3·NCT01059630·413 enrolled

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04703686·67 enrolled

CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06567366·45 enrolled

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04739813·55 enrolled

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02529852·59 enrolled

A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT00825149·137 enrolled

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05846750·59 enrolled

Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting·CChristian Buske·Phase 2·NCT03322865·56 enrolled

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT02453087·66 enrolled

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT05364424·43 enrolled

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07240194·24 enrolled

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Recruiting·UUniversity College, London·Phase 2·NCT06071871·99 enrolled

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated· Roche logo

Roche·Phase 1·NCT05219513·53 enrolled

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT05797948·20 enrolled

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Completed· Roche logo

Roche·Phase 3·NCT01332968·1,401 enrolled

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Withdrawn· Roche logo

Roche·Phase 1·NCT03369964

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01995669·66 enrolled

Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

Terminated·KKlinikum Stuttgart·Phase 1·NCT04073147·4 enrolled

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Completed·JJoseph Tuscano·Phase 1·NCT04578600·8 enrolled

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Active, not recruiting·BBeth Christian·Phase 1·NCT02992522·22 enrolled

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05798156·125 enrolled

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT01992653·85 enrolled

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Active, not recruiting· Pfizer logo

Pfizer·Phase 1/2·NCT05896163·24 enrolled

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed·UUniversity Health Network, Toronto·Phase 2·NCT02750670·30 enrolled

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Completed· Roche logo

Roche·Phase 2·NCT00576758·175 enrolled

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Completed· Roche logo

Roche·Phase 1·NCT03467373·111 enrolled

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Completed·UUniversity of Washington·Phase 2·NCT05169658·42 enrolled

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT03223610·155 enrolled

Follicular Lymphoma24 trials

Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Unknown status·MMeir Medical Center·Phase 2·NCT04934930·40 enrolled

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting·LLudwig-Maximilians - University of Munich·Phase 2·NCT05387616·98 enrolled

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting·EEmory University·Phase 2·NCT04883437·49 enrolled

Show 21 more trials

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Terminated·SSecuraBio·Phase 1/2·NCT02391545·55 enrolled

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Active, not recruiting·—·Phase 2·NCT05783596·47 enrolled

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed· Roche logo

Roche·Phase 4·NCT03817853·114 enrolled

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Completed·SSwiss Cancer Institute·Phase 1·NCT02877550·25 enrolled

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Terminated·UUniversity of Washington·Phase 2·NCT03401853·18 enrolled

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma

Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1/2·NCT03980171·50 enrolled

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06961500·133 enrolled

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Recruiting·UUniversity of Birmingham·Phase 2·NCT05848765·284 enrolled

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting·JJoseph Tuscano·Phase 2·NCT04450173·40 enrolled

First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed·PProf. Dr. Wolfgang Hiddemann·Phase 2·NCT03492775·46 enrolled

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

Completed· Roche logo

Roche··NCT04034056·299 enrolled

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT06284122·790 enrolled

Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06474481·30 enrolled

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Completed· BeiGene logo

BeiGene·Phase 2·NCT03332017·217 enrolled

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT03890289·5 enrolled

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT02631577·38 enrolled

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

Terminated·UUniversity of Chicago·Phase 1/2·NCT04722601·2 enrolled

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Active, not recruiting·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT04962126·15 enrolled

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Unknown status·HHeidelberg University·Phase 2·NCT03341520·89 enrolled

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Withdrawn· Incyte logo

Incyte·Phase 3·NCT04796922

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02871219·96 enrolled

Diffuse Large B-Cell Lymphoma16 trials

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02600897·114 enrolled

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02611323·133 enrolled

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT02257567·331 enrolled

Show 13 more trials

Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Terminated·UUniversity of Chicago·Phase 2·NCT02420210·2 enrolled

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated· Roche logo

Roche·Phase 1/2·NCT03135262·29 enrolled

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02729896·36 enrolled

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02596971·91 enrolled

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04313608·23 enrolled

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04657302·30 enrolled

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

Not yet recruiting·RRuijin Hospital··NCT06656234·200 enrolled

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT02220842·96 enrolled

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Terminated· Roche logo

Roche·Phase 3·NCT01287741·1,418 enrolled

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT07480850·40 enrolled

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05211336·14 enrolled

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Terminated· Roche logo

Roche·Phase 1/2·NCT02624986·25 enrolled

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Completed· Roche logo

Roche·Phase 2·NCT01414855·100 enrolled

Mantle Cell Lymphoma10 trials

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT03311126·21 enrolled

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07261163·37 enrolled

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting·—·Phase 2·NCT06054776·40 enrolled

Show 7 more trials

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02896582·86 enrolled

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT02736617·10 enrolled

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06192888·39 enrolled

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06504199·39 enrolled

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Recruiting·AAustralasian Leukaemia and Lymphoma Group·Phase 2·NCT05833763·42 enrolled

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06656221·29 enrolled

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

Recruiting·OOHSU Knight Cancer Institute·Phase 1/2·NCT06357676·27 enrolled

56 more indications

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma4 trials

Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06547944·30 enrolled

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Recruiting·ZZulfa Omer·Phase 2·NCT06978088·34 enrolled

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04434196·16 enrolled

Show 1 more trial

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02406742·47 enrolled

Membranous Nephropathy3 trials

REmission in Membranous Nephropathy International Trial (REMIT)

Withdrawn·TThe University of Queensland·Phase 3·NCT06120673

OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)

Recruiting·HHuashan Hospital·Phase 3·NCT06781944·144 enrolled

Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

Unknown status·QQianfoshan Hospital··NCT05845762·30 enrolled

CLL3 trials

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT05950997·89 enrolled

Safe Accelerated Venetoclax Escalation in CLL

Active, not recruiting·—·Phase 1·NCT04843904·40 enrolled

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting·MMassachusetts General Hospital·Phase 2·NCT04560322·40 enrolled

Relapsed/Refractory3 trials

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL

Completed·GGerman CLL Study Group·Phase 2·NCT03787264·46 enrolled

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02417285·75 enrolled

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Completed·AAcerta Pharma BV·Phase 1·NCT02296918·69 enrolled

Systemic Lupus Erythematosus2 trials

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04963296·303 enrolled

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Active, not recruiting·AArtiva Biotherapeutics, Inc.·Phase 1·NCT06265220·51 enrolled

Lenalidomide2 trials

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Withdrawn·UUniversity of California, San Diego·Phase 2·NCT02371590

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT03863184·37 enrolled

Treatment2 trials

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

Completed· Roche logo

Roche·Phase 1·NCT04826003·54 enrolled

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04722172·55 enrolled

B-cell Malignancies2 trials

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Terminated· Gilead logo

Gilead·Phase 1·NCT02457598·203 enrolled

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT04599634·11 enrolled

Locally Advanced2 trials

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT03539484·26 enrolled

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02324257·149 enrolled

Richter's Transformation2 trials

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Terminated·NNorthwell Health·Phase 2·NCT03145480·3 enrolled

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Recruiting·CChristine Ryan·Phase 2·NCT06043674·70 enrolled

Malignant Disease2 trials

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Completed· Roche logo

Roche·Phase 1/2·NCT00517530·134 enrolled

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Completed· Roche logo

Roche·Phase 1·NCT01680991·48 enrolled

Immune Thrombocytopenia2 trials

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06094881·60 enrolled

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05995054·110 enrolled

Targeted Therapy1 trial

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Recruiting·RRuijin Hospital·Phase 2·NCT06793189·145 enrolled

Macroglobulinemia1 trial

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT02962401·50 enrolled

Urothelial Cancer1 trial

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Withdrawn·WWeill Medical College of Cornell University·Phase 1·NCT05894447

CLL/SLL1 trial

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

Terminated·SSecuraBio·Phase 1·NCT02292225·3 enrolled

Elective1 trial

A Study Of The Selective PKC-β Inhibitor MS- 553

Terminated·MMingSight Pharmaceuticals, Inc·Phase 1/2·NCT03492125·60 enrolled

Chemotherapy1 trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting·NNew York Medical College·Phase 2·NCT02393157·25 enrolled

Glomerulonephritis1 trial

Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Recruiting·MMayo Clinic·Phase 2·NCT06295770·20 enrolled

Refractory1 trial

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05823701·23 enrolled

Small Cell Lung Cancer1 trial

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Recruiting· Roche logo

Roche·Phase 1·NCT07107490·122 enrolled

Advanced or Metastatic NSCLC1 trial

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Completed·NNeoTX Therapeutics Ltd.·Phase 2·NCT04880863·38 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Completed·—·Phase 2·NCT02867384·181 enrolled

Central Nervous System Lymphoma1 trial

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Recruiting·PProvidence Health & Services·Phase 2·NCT06175000·28 enrolled

Lupus Nephritis1 trial

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Completed· Roche logo

Roche·Phase 2·NCT02550652·126 enrolled

High Risk1 trial

Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02670317·1 enrolled

Colorectal Adenocarcinoma1 trial

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Terminated· Roche logo

Roche·Phase 1·NCT03866239·47 enrolled

NHL1 trial

Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruiting·—··NCT05968001·400 enrolled

Acute Lymphoblastic Leukemia1 trial

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT04920968·124 enrolled

Granulomatosis with Polyangiitis1 trial

Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06940661·33 enrolled

Melanoma1 trial

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Completed· Roche logo

Roche·Phase 1·NCT04551352·20 enrolled

Advanced Hematologic Malignancies1 trial

FT516 in Subjects With Advanced Hematologic Malignancies

Terminated·FFate Therapeutics·Phase 1·NCT04023071·72 enrolled

End-Stage Renal Disease1 trial

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Completed· Roche logo

Roche·Phase 1·NCT02586051·24 enrolled

Leukemia1 trial

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03759184·1 enrolled

DLBCL1 trial

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07326371·24 enrolled

Chronic Lymphocytic Leukaemia (CLL)1 trial

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting·GGerman CLL Study Group·Phase 3·NCT04608318·897 enrolled

Allogeneic Stem Cell Transplantation1 trial

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Terminated·GGerman CLL Study Group·Phase 2·NCT03153514·3 enrolled

Relapsed or Refractory1 trial

Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT02987400·22 enrolled

TIA1 trial

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Active, not recruiting·—·Phase 2·NCT03580928·72 enrolled

Idiopathic Nephrotic Syndrome1 trial

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05627557·85 enrolled

Trial1 trial

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Completed·UUniversity of Ulm·Phase 2·NCT02758665·41 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02174172·158 enrolled

Immunotherapy1 trial

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Active, not recruiting·AAcerta Pharma BV·Phase 3·NCT03836261·984 enrolled

TED1 trial

Avo In R/R And Previously Untreated MCL

Recruiting·AAustin I Kim·Phase 1/2·NCT04855695·72 enrolled

Remission1 trial

PR3-AAV Resilient Remission or PRRR

Terminated·MMayo Clinic·Phase 2·NCT05376319·6 enrolled

Monotherapy1 trial

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Terminated·FFate Therapeutics·Phase 1·NCT04245722·98 enrolled

Richter's Syndrome1 trial

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Completed·UUniversity of California, San Diego·Phase 1·NCT03113695·4 enrolled

Breast Cancer1 trial

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated·MMayo Clinic·Phase 1·NCT03432741·17 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Terminated·PPolish Lymphoma Research Group·Phase 2·NCT03229382·1 enrolled

Efficacy1 trial

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Recruiting·SSimcha IL-18, Inc.·Phase 1/2·NCT04787042·316 enrolled

Anti-CD20 Monoclonal Antibody1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Recruiting·IInnoCare Pharma Inc.·Phase 1·NCT06351527·78 enrolled

Post-Transplant Lymphoproliferative Disorder1 trial

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Withdrawn·—·Phase 2·NCT03086395

Nephrotic Syndrome1 trial

Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome

Not yet recruiting· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT07233330·10 enrolled

B-cell Lymphoid Malignancies1 trial

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Completed· BeiGene logo

BeiGene·Phase 1·NCT02569476·119 enrolled

Newly Diagnosed1 trial

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05322733·25 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 1, 2013

GAZYVA

NDA BLA125486

Nov 1, 2013

GAZYVA

BLA BLA125486

Jun 27, 2014

GAZYVA

NDA BLA125486

Dec 24, 2014

GAZYVA

NDA BLA125486

Sep 23, 2015

GAZYVA

NDA BLA125486

Feb 26, 2016

GAZYVA

NDA BLA125486

Nov 16, 2017

GAZYVA

NDA BLA125486

Nov 16, 2017

GAZYVA

NDA BLA125486

Mar 27, 2020

GAZYVA

NDA BLA125486

Feb 14, 2022

GAZYVA

NDA BLA125486

Jul 12, 2022

GAZYVA

NDA BLA125486

Jul 27, 2022

GAZYVA

NDA BLA125486

Oct 17, 2025

GAZYVA

NDA BLA125486

Oct 17, 2025

GAZYVA

NDA BLA125486

Dec 17, 2025

GAZYVA

NDA BLA125486

Sources

References

[1]
ClinicalTrials.gov — 273 trial records for Obinutuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Gazyva drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Obinutuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Obinutuzumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA125486). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: B-Lymphocyte Antigen CD20 Binding Agent[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche

Gazyva

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Chronic Lymphocytic Leukemia44 trials

Lymphoma33 trials

Follicular Lymphoma24 trials

Diffuse Large B-Cell Lymphoma16 trials

Mantle Cell Lymphoma10 trials

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma4 trials

Membranous Nephropathy3 trials

CLL3 trials

Relapsed/Refractory3 trials

Systemic Lupus Erythematosus2 trials

Lenalidomide2 trials

Treatment2 trials

B-cell Malignancies2 trials

Locally Advanced2 trials

Richter's Transformation2 trials

Malignant Disease2 trials

Immune Thrombocytopenia2 trials

Targeted Therapy1 trial

Macroglobulinemia1 trial

Urothelial Cancer1 trial

CLL/SLL1 trial

Elective1 trial

Chemotherapy1 trial

Glomerulonephritis1 trial

Refractory1 trial

Small Cell Lung Cancer1 trial

Advanced or Metastatic NSCLC1 trial

Real-world Study1 trial

Peripheral Blood Stem Cell Transplantation1 trial

Central Nervous System Lymphoma1 trial

Lupus Nephritis1 trial

High Risk1 trial

Colorectal Adenocarcinoma1 trial

NHL1 trial

Acute Lymphoblastic Leukemia1 trial

Granulomatosis with Polyangiitis1 trial

Melanoma1 trial

Advanced Hematologic Malignancies1 trial

End-Stage Renal Disease1 trial

Leukemia1 trial

DLBCL1 trial

Chronic Lymphocytic Leukaemia (CLL)1 trial

Allogeneic Stem Cell Transplantation1 trial

Relapsed or Refractory1 trial

TIA1 trial

Idiopathic Nephrotic Syndrome1 trial

Trial1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Immunotherapy1 trial

TED1 trial

Remission1 trial

Monotherapy1 trial

Richter's Syndrome1 trial

Breast Cancer1 trial

Efficacy and Safety1 trial

Efficacy1 trial

Anti-CD20 Monoclonal Antibody1 trial

Post-Transplant Lymphoproliferative Disorder1 trial

Nephrotic Syndrome1 trial

B-cell Lymphoid Malignancies1 trial

Newly Diagnosed1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News